Effect of Aslagh and Uriculotherapy in Polycystic Ovary Syndrom

Phase 3

Recruiting

• Conditions: Polycystic Ovary Syndrom.; Polycystic ovarian syndrome; E28.2

• Registration Number: IRCT20200407046980N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 110

Inclusion Criteria

Women 18-43 years old
Having Rotterdam Criteria for Diagnosing Polycystic Ovary Syndrome
Polycystic Ovary Syndrom Patients with Oligomenorrhea

Exclusion Criteria

Having Hyperprolactinemia, Hypothyroidism, Adrenal Insufficiency, Cushing's Disease and Diabetes
Being in breastfeeding
Taking Dopaminergic Drugs
Taking hormonal druges for a month before entering the study
History of hypersensitivity to herbal medicines
Lack of drastic lifestyle changes in 4 areas: exercise, sleep, diet, patient excretion pattern (eg taking laxative ) from 2 weeks before the start of the study until the end of the study time

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of menstrual cycles. Timepoint: At the beginning of the study (before the intervention), one month, two months and three months after the intervention and one month after the end of the intervention. Method of measurement: questionnaire.

Secondary Outcome Measures

Name	Time	Method
Acne. Timepoint: At the beginning of the study (before the intervention), one month, two months and three months after the intervention and one month after the end of the intervention. Method of measurement: GAGS Global Scoring System.;Hirsutism. Timepoint: At the beginning of the study (before the intervention), one month, two months and three months after the intervention and one month after the end of the intervention. Method of measurement: Freeman Galloway's table.